Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Stock Holdings Boosted by Robeco Institutional Asset Management B.V.

Robeco Institutional Asset Management B.V. lifted its position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 3.5% during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 103,481 shares of the biopharmaceutical company's stock after purchasing an additional 3,487 shares during the period. Robeco Institutional Asset Management B.V. owned about 0.08% of Alnylam Pharmaceuticals worth $27,942,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also made changes to their positions in ALNY. Whipplewood Advisors LLC grew its stake in Alnylam Pharmaceuticals by 208.8% during the 1st quarter. Whipplewood Advisors LLC now owns 105 shares of the biopharmaceutical company's stock valued at $28,000 after purchasing an additional 71 shares in the last quarter. Bessemer Group Inc. raised its position in shares of Alnylam Pharmaceuticals by 176.9% in the 1st quarter. Bessemer Group Inc. now owns 108 shares of the biopharmaceutical company's stock valued at $29,000 after purchasing an additional 69 shares in the last quarter. Larson Financial Group LLC boosted its stake in shares of Alnylam Pharmaceuticals by 187.2% during the 4th quarter. Larson Financial Group LLC now owns 112 shares of the biopharmaceutical company's stock valued at $26,000 after buying an additional 73 shares during the last quarter. Park Square Financial Group LLC purchased a new position in shares of Alnylam Pharmaceuticals during the 4th quarter valued at approximately $28,000. Finally, Colonial Trust Co SC acquired a new stake in shares of Alnylam Pharmaceuticals during the fourth quarter worth approximately $35,000. 92.97% of the stock is currently owned by hedge funds and other institutional investors.

Alnylam Pharmaceuticals Stock Performance

Alnylam Pharmaceuticals stock traded down $4.03 during midday trading on Tuesday, reaching $322.06. 1,240,063 shares of the stock traded hands, compared to its average volume of 858,508. Alnylam Pharmaceuticals, Inc. has a fifty-two week low of $205.87 and a fifty-two week high of $327.21. The company has a current ratio of 3.04, a quick ratio of 2.98 and a debt-to-equity ratio of 8.88. The firm has a market cap of $41.99 billion, a price-to-earnings ratio of -154.10 and a beta of 0.23. The firm has a fifty day moving average price of $289.81 and a two-hundred day moving average price of $264.42.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last issued its quarterly earnings data on Thursday, May 1st. The biopharmaceutical company reported ($0.44) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.37) by ($0.07). Alnylam Pharmaceuticals had a negative return on equity of 510.31% and a negative net margin of 11.49%. The business had revenue of $594.19 million for the quarter, compared to analyst estimates of $584.32 million. During the same quarter in the prior year, the firm posted ($0.16) earnings per share. The business's quarterly revenue was up 20.2% on a year-over-year basis. On average, equities research analysts forecast that Alnylam Pharmaceuticals, Inc. will post -1.7 earnings per share for the current year.

Analyst Ratings Changes

ALNY has been the topic of several recent analyst reports. Chardan Capital upped their price target on shares of Alnylam Pharmaceuticals from $300.00 to $325.00 and gave the company a "buy" rating in a report on Friday, May 2nd. Royal Bank Of Canada upped their target price on shares of Alnylam Pharmaceuticals from $310.00 to $330.00 and gave the company an "outperform" rating in a research note on Friday, March 21st. Wells Fargo & Company increased their price target on shares of Alnylam Pharmaceuticals from $287.00 to $333.00 and gave the stock an "equal weight" rating in a research report on Monday. Morgan Stanley lowered their price objective on Alnylam Pharmaceuticals from $284.00 to $268.00 and set an "equal weight" rating for the company in a report on Friday, April 11th. Finally, HC Wainwright restated a "buy" rating and set a $500.00 price objective on shares of Alnylam Pharmaceuticals in a research note on Wednesday, April 2nd. One analyst has rated the stock with a sell rating, four have issued a hold rating and twenty have given a buy rating to the company's stock. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $340.00.

Insiders Place Their Bets

In related news, CEO Yvonne Greenstreet sold 19,297 shares of the company's stock in a transaction dated Monday, June 2nd. The shares were sold at an average price of $306.00, for a total value of $5,904,882.00. Following the completion of the sale, the chief executive officer owned 48,948 shares of the company's stock, valued at $14,978,088. This represents a 28.28% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. 1.20% of the stock is owned by insiders.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.